The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use and duration of chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy (tx).
Davinia Shien Seah
No relevant relationships to disclose
Ines Maria Vaz Duarte Luis
No relevant relationships to disclose
Erin Macrae Olson
No relevant relationships to disclose
Jessica Sohl
No relevant relationships to disclose
Georgia Litsas
No relevant relationships to disclose
Eric Winer
Research Funding - Genentech
Nancy U. Lin
Consultant or Advisory Role - Genentech (U); GlaxoSmithKline; Novartis
Research Funding - Boehringer Ingelheim; Genentech; GlaxoSmithKline; Infinity
Harold J. Burstein
No relevant relationships to disclose